Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Kansas City, Kansas 66160


RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of indole-3-carbinol may prevent cancer. PURPOSE: This randomized phase I trial is studying the side effects and best dose of indole-3-carbinol and to see how well it works compared to placebo in preventing cancer in healthy participants.

Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose of indole-3-carbinol in healthy participants. - Determine the safety and tolerability of this drug in these participants. - Determine the pharmacokinetics of this drug in these participants. Secondary - Determine the effects of this drug on selected markers of sexual function in these participants. - Determine the effects of this drug on markers of susceptibility to cancer in these participants. OUTLINE: This is a randomized, double-blind, placebo-controlled, dose-escalation study. Participants at each dose level are randomized to 1 of 2 treatment arms. - Arm I: Participants receive a single dose of oral indole-3-carbinol on day 1. - Arm II: Participants receive a single dose of oral placebo on day 1. Cohorts of 3 participants receive escalating doses of indole-3-carbinol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 participants experiences dose-limiting toxicity. An additional cohort of 3 participants is treated at the MTD. Participants are followed on days 2, 3, and 6. PROJECTED ACCRUAL: A total of 24 participants (18 in arm I and 6 in arm II) will be accrued for this study.


DISEASE CHARACTERISTICS: - Healthy participants - Non-smoker - No drug abuse, as determined by urine cotinine and baseline drug screen PATIENT CHARACTERISTICS: Age - 18 to 70 Performance status - Not specified Life expectancy - At least 12 months Hematopoietic - Absolute granulocyte count > 1,500/mm^3 - Hemoglobin > 10 g/dL Hepatic - Bilirubin < 1.8 mg/dL - AST and ALT < 110 U/L - Alkaline phosphatase < 300 U/L Renal - Creatinine < 2.0 mg/dL - Albumin > 3.0 g/dL Pulmonary - No asthma Other - Not pregnant or nursing - Negative pregnancy test - Weight within 20% of ideal body weight by the Metropolitan Life table - No serious drug allergies - No arthritis - No acute, unstable, chronic, or recurring medical condition - No strict vegetarians - No diabetes - No evidence of an active malignancy - No other serious intolerance or allergies - Mild seasonal allergies allowed - No other serious acute or chronic illness - None of the following chronic conditions: - Headaches - Dysphoria - Fatigue - Dizziness - Blurred vision - Insomnia - Rhinorrhea - Nausea - Vomiting - Abdominal pain - Diarrhea - Constipation - Premenstrual syndrome - Cessation of menses within the past 10 days (menstruating women only) PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Concurrent oral contraceptives allowed Radiotherapy - Not specified Surgery - Not specified Other - More than 21 days since prior medications, herbal products, dietary supplements, or high-dose vitamins - More than 3 months since prior investigational drugs - At least 14 days since prior and no concurrent ingestion of cruciferous vegetables, including any of the following: - Broccoli - Cabbage, including coleslaw - Cauliflower - Bok-choy - Brussels sprouts - Collards - Kale - Kohlrabi - Mustard greens - Rutabaga - Turnip - Watercress - At least 7 days since prior and no concurrent alcohol consumption - At least 48 hours since prior ingestion of grapefruit-containing foods and beverages - No concurrent chronic drug therapy - No other concurrent supplements, including dietary supplements, vitamins, herbal products, or over-the-counter medications



Primary Contact:

Principal Investigator
Gregory Reed, PhD
University of Kansas

Backup Contact:


Location Contact:

Kansas City, Kansas 66160
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.